Supplementary Information for

An Integrated Paper-based Microfluidic Platform for Screening of Early-Stage Alzheimer's Disease by Detecting of Aβ42

Sixuan Duan^{1,2‡}, Tianyu Cai^{1,2‡}, Lizhe Chen^{1,2}, Xiaoyan Wang^{1,2}, Shuailong Zhang³,

Bing Han^{1,2}, Eng Gee Lim^{1,2*}, Kai Hoettges², Yong Hu⁴, Pengfei Song^{1,2*}

¹ School of Advanced Technology, Xi'an Jiaotong-Liverpool University, Suzhou, China, 215000

² Department of Electrical and Electronic Engineering, University of Liverpool, Liverpool, UK,

L69 7ZX

³ School of Integrated Circuits and Electronics, Beijing Institute of Technology, Beijing, 100081

⁴ School of Mechanical and Aerospace Engineering, Jilin University, Changchun, China, 130022

*Corresponding author:

Pengfei Song: pengfei.song@xjtlu.edu.cn

Eng Gee Lim: enggee.lim@xjtlu.edu.cn

Figure S1. Additional features and mechanisms of the paper-based microfluidic chip device, along with fabrication process

Figure S2. Illustration of preparations for paper-based chips before use.

Figure S3. Design of appearance, functions, and interactions of the RAPID platform, along with fabrication and assembling process.

Figure S4. Design of companioned Android-based APP for interacting with the RAPID platform and communicating with other terminals.

Figure S5. Results of experiment evaluating infereference of plasma background color to colorimetric assay.

Figure S6. Illustration of steps for agreement analysis between the clinical performance of the RAPID and that of the gold standard commercial ELISA.

Table S1. Design and fabrication parameters of paper-based chip.

Table S2. Design and fabrication parameters of RAPID platform.

Table S3. Models of electronic components used in the RAPID platform.

Table S4. Raw data for results of specimens tested by RAPID and commercial ELISA.

Table S5. One-test cost of the paper-based chip.

Table S6. Cost of the RAPID platform.

Table S7. Comparison between our RAPID and the commercial ELISA.



Figure S1. Additional features and mechanisms of the paper-based microfluidic chip device, along with fabrication process. (a) The structure and mechanism for flow speeding up. An additional meniscus-capillary force was introduced by the air gap formed between paper channels and supporting PMMA separated by a carved wax paper. (b), Illustration of stop mechanism of the reagents flushed into the test zone, utilizing the equilibrium between the liquid's viscous drag force and the capillary force of both paper and air gap. (c), The fabrication process of the paper-based device. Step 1: Transfer designed patterns to the paper by wax printing; Step 2: detach patterns and drill align/mount holes through laser cutting; Step 3: heat the paper to form hydrophobic boundaries by melting printed wax throughout paper; Step 4: assemble paper and two layers of PMMA cases with M2 screws and nuts.



Figure S2. Illustration of preparations for paper-based chips before use. (a) Biofunctionalization of the test zone by potassium periodate (KIO₄) to strengthen binding between proteins and paper: To perform this process, we spotted KIO₄ aqueous solution (0.031M, pH=5) with 1.5 μ L under 65 °C, repeating every 2 min for 20 times. Hydroxyl groups on cellulose paper changed to aldehyde groups, capable to achieve strong binding of proteins via covalent bonds. (b) Preparation of spiked samples for obtaining calibration curve and loading reagents on the paper-based chip: Firstly, capture antibody (3 μ L) was added into the test zone, while HRP conjugated antibody (3 μ L) and TMB substrate (3 μ L) were added into storage 1 and 2 respectively, after which paper-based chip was dried for 10 min under room temperature; Secondly, blocking buffer (3 μ L) was added into the test zone and then dried for 10 min under room temperature; Thirdly, spiked sample (3 μ L) was added into the test zone and then dried for 10 min under room temperature; Thirdly, spiked sample (3 μ L) was added into the test zone and then dried for 10 min under room temperature; Thirdly, spiked sample (3 μ L) was added into the test zone and then dried for 10 min under room temperature; Thirdly, spiked sample (3 μ L) was added into the test zone and then dried for 10 min under room temperature. The paper-based chip was shaded by a 3D printed apparatus to avoid light decomposition of TMB substrate during all drying steps.



Figure S3. Design of appearance, functions, and interactions of the RAPID platform, along with fabrication and assembling process. (a), Three-view drawing of the appearance of the RAPID platform. (b), Flowchart of interactions between users and the RAPID platform. (c), Fabrication and assembling process of the RAPID platform. Step 1: Computer-aided design (CAD) design for the appearance and structure of the RAPID platform by Solidworks; Step 2: Fabrication of shells and supporting-frame structures of the RAPID platform by 3D printing; Step 3: Assembling of 3D-printing structures with electronic components: microcontroller, screen, sensor, etc.



Figure S4. Design of companioned Android-based APP for interacting with the RAPID platform and communicating with other terminals. (a) Flowchart of the companioned Android-based APP: The APP connects the RAPID platform through Bluetooth to control testing and obtain results, where the results can also be transmitted to other kinds of (smart-mobile) devices by Bluetooth; It can also send the results to the hospital to obtain doctor's diagnosis and follow suggestions. (b) Log-in and results interface (along with recent history data, which presented by a curve of the target over time) of the Android-based APP.



Figure S5. Results of an experiment evaluating interference of plasma background color to colorimetric assay.



Figure S6. Illustration of steps for agreement analysis between the clinical performance of the RAPID and that of the gold standard commercial ELISA.

Design		Fabrication		
Overall	89 mm × 78		Wax printer	Xerox 8580DN
dimensions	$mm \times 5 mm$			
	(L×W×H)			
Valve diameter	34 mm		Laser cutter	Han's Yueming
				СМА0604-В-А
Channel width	2.8 mm		Laser parameter	Intensity: 10%
			for paper	Speed: 50 mm/s
Overlap width	2 mm		Laser parameter	Intensity: 40%
			for PMMA	Speed: 35 mm/s
Paper model	Whatman No. 1		Hot plate	Cole-palmer
	chromatography			7"×7"
	paper			
Flow rate	2.24 mm/s		Heat parameter	150 °C, 60 s
(modified)				

Table S1. Design and fabrication parameters of paper-based chip.

Design		Fabrication		
Overall	179.66 × mm		3D printer	Ultimaker S5
dimensions	× 143 mm ×			
	95.23 mm			
Respond rate	76±0.6ms		Material	Ultimaker
				Tough PLA

Table S2. Design and fabrication parameters of RAPID platform.

Component	Model
Battery module	Ywrobot
Servo motor of valve driver	Feetech SCS2332
Microcontroller	Arduino Uno R3
Bluetooth module	HM-10
Touch screen	Mzdesign ATF050
Illuminant screen	WaveShare 0.96 LCD
RGB sensor	ISL29125

Table S3. Models of electronic components used in the RAPID platform.

Specimen number	Result of RAPID (pg)	Result of commercial
		ELISA (pg)
1	282.56	250.65
2	108.24	160.25
3	407.02	436.51
4	227.09	270.85
5	163.18	122.37
6	214.75	305.2
7	26.69	20.62
8	36.28	27.29
9	14.67	18.4
10	13.71	25.07
11	41.15	35.67
12	306.34	401.06
13	198.73	154.9
14	203.83	243.37
15	302.35	348.13
16	208.39	256.83
17	145.23	122.21
18	259.38	214.52
19	202.33	245.29
20	111.53	83.75
21	189.22	181.83
22	289.34	305.2
23	16.33	18.25
24	10.35	14.91

Table S4. Raw data for results of specimens tested by RAPID and commercial ELISA.

Item	Amount (\$)
Paper, wax, PMMA, and screw/nut	0.41
Capture antibody	0.47
Blocking buffer	0.08
HRP-conjugated antibody	0.02
TMB substrate	0.004
PBS buffer	0.0001
Total	0.98

Table S5. One-test cost of the paper-based chip.

Table S6. Cost of the RAPID platform.

Item	Amount (\$)
3D printing material	25.50
Electronic components	78.67
Other component/material	3.53
Total	107.7

	RAPID	Commercial ELISA
One-test cost	0.98 \$	13.88 \$
Instrument cost	107.7 \$	Over 3000 \$
Time to result	30 min	1.5 h
Sample volume	3 μL	100 µL
Portability	Yes	No
Capability of IOT	Yes	No
Sample-in-answer-out	Yes	No

Table S7. Comparison between our RAPID and the commercial ELISA.

ELISA is the most widely used analytical assay as it is the gold standard for detecting protein biomarkers in disease-related clinical samples, especially in low-resource settings [1-4]. This work mainly solves the problems of manual pipetting, low reproducibility, low efficiency, and the requirement for trained individuals to operate commercial ELISA. Meanwhile, it provides a feasible solution for early screening of AD. Therefore, we mainly compared the RAPID with commercial ELISA. In addition, commercial ELISA kits typically contain 96 wells (96 experiments). In contrast, our RAPID was the cost of one assay. Therefore, we divided the total reagent price of the commercial ELISA by 96 to obtain the price of a single assay. In addition, we tested 22 artificial plasma samples with RAPID and commercial ELISA. Among them, the commercial ELISA kit results were obtained from plate readers. The RAPID results were obtained from the platform's RGB sensor. Therefore, we also compared the prices of these two readout devices here.

References:

[1] C.-M. Cheng, A.W. Martinez, J. Gong, C.R. Mace, S.T. Phillips, E. Carrilho, K.A. Mirica, G.M. Whitesides, based ELISA, Angewandte Chemie, (2010).

[2] A. Thiha, F. Ibrahim, A colorimetric enzyme-linked immunosorbent assay (ELISA) detection platform for a point-of-care dengue detection system on a lab-on-compactdisc, Sensors, 15 (2015) 11431-11441.

[3] X. Liu, C. Cheng, A. Martinez, K. Mirica, X. Li, S. Phillips, M. Mascarenas, G. Whitesides, A portable microfluidic paper-based device for ELISA, 2011 IEEE 24th international conference on micro electro mechanical systems, IEEE, 2011, pp. 75-78.

[4] R.C. Murdock, L. Shen, D.K. Griffin, N. Kelley-Loughnane, I. Papautsky, J.A. Hagen, Optimization of a paper-based ELISA for a human performance biomarker, Analytical chemistry, 85 (2013) 11634-11642.